•
MicroPort Scientific Corp (HKG: 0853), a leading medical device company, has seen its subsidiaries Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) and spin-off MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160) unveil their financial forecasts for the first half of 2024, along with business updates. MedBot anticipates a significant year-on-year…
•
Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced that its Toumai endoscopic surgery robot has received CE qualification from the European Union, allowing the product to be marketed and used for urology, general surgery, thoracic surgery, and gynecological endoscopic surgeries within the EU. The Toumai robot is the…
•
Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced its financial results for 2023, reporting a substantial year-on-year (YOY) increase of 384.2%, with revenues reaching RMB 104.6 million (USD 14.43 million). The significant growth is attributed to the sales of its core products: the Toumai endoscopic surgery robot, SkyWalker…
•
Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced that it has received market approval from China’s National Medical Products Administration (NMPA) for its R-ONE vascular intervention surgical robot. The robot was introduced by Cathbot, a joint venture between MicroPort and French firm Robocath S.A.S in China. R-ONE, a…
•
Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its innovative navigation and positioning system, the SkyWalker hip and knee joint replacement surgery robot. This marks the first approval of an in-house developed mechanical arm…